The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Baseline extent of damage predicts spinal radiographic progression in Korean patients with ankylosing spondylitis treated with golimumab

  • Lee, Jeong Seok (Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital) ;
  • Song, Yeong Wook (Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital) ;
  • Kim, Tae Hwan (Division of Rheumatology, Department of Internal Medicine, Hanyang University Seoul Hospital) ;
  • Chung, Won Tae (Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital) ;
  • Lee, Seung Geun (Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital) ;
  • Park, Sung Hwan (Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea) ;
  • Song, Gwan Gyu (Division of Rheumatology, Department of Internal Medicine, Korea University Guro Hospital) ;
  • Yu, Dae Young (Janssen Korea, Medical Affairs) ;
  • Xu, Stephen (Department of Biostatistics, Janssen Research & Development, LLC, Spring House) ;
  • Lee, Eun Young (Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital)
  • Received : 2016.02.19
  • Accepted : 2016.05.22
  • Published : 2018.05.01
⟨ Previous Next ⟩

Abstract

Background/Aims: For patients with ankylosing spondylitis (AS), golimumab has consistent efficacy in controlling disease activity over 5 years but its benefit in preventing radiographic progression was less clear at 4 years. To predict radiographic progression, we analyzed the baseline characteristics of AS patients in a Korean population. Methods: Sixty-eight Korean patients with AS participated in the phase 3, multicenter, randomized, placebo-controlled, double-blind trial (GO-RAISE) which has previously been described. Baseline modified stoke AS spine score (mSASSS) and change in mSASSS from baseline (${\Delta}mSASSS$) until week 208 were analyzed in the Korean patients enrolled in the GO-RAISE study. Results: Although Korean patients had lower baseline mSASSS compared to non-Korean patients and received active management, radiographic progression was not prevented. Korean patients who did not undergo radiographic progression of spinal lesions of AS were younger and had shorter symptomatic duration, lower Bath AS functional and metrology indices, better chest expansion, and lower baseline mSASSS. The baseline mSASSS and ${\Delta}mSASSS$ were positively correlated in Korean AS patients (p < 0.001). Radiographic progression was more prevalent (80.0%) when baseline mSASSS > 10 and less common (13.0%) with baseline mSASSS = 0. Conclusions: In Korean AS patients, radiographic progression of the spine after 4 years was predicted effectively by the initial severity of the spinal lesion(s) in patients treated with golimumab.

Keywords

References

  1. Landewe R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 2009;68:863-867. https://doi.org/10.1136/ard.2008.091793
  2. Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127-129. https://doi.org/10.1136/ard.2004.020503
  3. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005;64:1462-1466. https://doi.org/10.1136/ard.2004.033472
  4. Baraliakos X, Listing J, Brandt J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 2007;46:1450-1453. https://doi.org/10.1093/rheumatology/kem166
  5. van der Heijde D, Landewe R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-1331. https://doi.org/10.1002/art.23471
  6. van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127. https://doi.org/10.1186/ar2794
  7. Braun J, Baraliakos X, Hermann KG, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis 2014;73:1107-1113. https://doi.org/10.1136/annrheumdis-2012-203075
  8. Deodhar A, Braun J, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis 2015;74:757-761. https://doi.org/10.1136/annrheumdis-2014-205862
  9. Baek HJ, Shin KC, Lee YJ, et al. Clinical features of adultonset ankylosing spondylitis in Korean patients: patients with peripheral joint disease (PJD) have less severe spinal disease course than those without PJD. Rheumatology (Oxford) 2004;43:1526-1531. https://doi.org/10.1093/rheumatology/keh373
  10. Kim TJ, Lee S, Joo KB, et al. The presence of peripheral arthritis delays spinal radiographic progression in ankylosing spondylitis: Observation Study of the Korean Spondyloarthropathy Registry. Rheumatology (Oxford) 2014;53:1404-1408. https://doi.org/10.1093/rheumatology/keu014
  11. Maksymowych WP. Spondyloarthritis in 2012: advances in pathogenesis through animal models and imaging. Nat Rev Rheumatol 2013;9:72-74. https://doi.org/10.1038/nrrheum.2012.233
  12. Maksymowych WP, Morency N, Conner-Spady B, Lambert RG. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis 2013;72:23-28. https://doi.org/10.1136/annrheumdis-2011-200859
  13. Baraliakos X, Listing J, Rudwaleit M, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007;66:910-915. https://doi.org/10.1136/ard.2006.066415
  14. Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor ${\alpha}$ inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013;65:2645-2654.
  15. Lee SH, Choi IA, Lee YA, et al. Human leukocyte antigen-B*2705 is the predominant subtype in the Korean population with ankylosing spondylitis, unlike in other Asians. Rheumatol Int 2008;29:43-46. https://doi.org/10.1007/s00296-008-0602-z
  16. Kim TJ, Kim TH. Clinical spectrum of ankylosing spondylitis in Korea. Joint Bone Spine 2010;77:235-240. https://doi.org/10.1016/j.jbspin.2009.11.015
  17. Lee JH, Jun JB, Jung S, et al. Higher prevalence of peripheral arthritis among ankylosing spondylitis patients. J Korean Med Sci 2002;17:669-673. https://doi.org/10.3346/jkms.2002.17.5.669
  18. Heuft-Dorenbosch L, van Tubergen A, Spoorenberg A, et al. The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. Arthritis Rheum 2004;51:154-159. https://doi.org/10.1002/art.20233

Cited by

  1. Effect of TNF‐inhibitor therapy on spinal structural progression in ankylosing spondylitis patients: A systematic review and meta‐analysis vol.23, pp.6, 2018, https://doi.org/10.1111/1756-185x.13829
  2. Risk Factors for Spinal Structural Damage in a Chinese Cohort With Ankylosing Spondylitis vol.28, pp.1, 2018, https://doi.org/10.1097/rhu.0000000000001658